Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | Director | December 03, 2021 | December 08, 2021 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | December 03, 2021 | December 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date December 03, 2021 · Filed December 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 107,807 |
Reported balance
After 2021-12-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-12-03 · Other · Acquired 107,807 · Balance 107,807 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 59,253 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 48,554 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 9,819 |
Reported balance
After 2021-12-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-12-03 · Other · Acquired 9,819 · Balance 9,819 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Family Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 7,373 |
Reported balance
After 2021-12-03 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-12-03 · Other · Acquired 7,373 · Balance 7,373 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decedents Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 80,324 |
Reported balance
Holding disclosure · report date 2021-12-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 80,324 |
Filing footnotes · ownership attribution and instrument terms
F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac.
F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 59,253 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 48,554 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein.
F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Family Trust except to the extent of his pecuniary interest therein.
F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decedents Trust except to the extent of his pecuniary interest therein.
Emergent BioSolutions Inc.
Report date December 03, 2021 · Filed December 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,018,644 |
Reported balance
After 2021-12-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-12-03 · Other · Acquired 3,018,644 · Balance 3,018,644 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 1,659,099 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 1,359,545 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 274,930 |
Reported balance
After 2021-12-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-12-03 · Other · Acquired 274,930 · Balance 274,930 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El Hibri Family Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 206,434 |
Reported balance
After 2021-12-03 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-12-03 · Other · Acquired 206,434 · Balance 206,434 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decendents Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 1,136,971 |
Reported balance
Holding disclosure · report date 2021-12-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,136,971 |
Filing footnotes · ownership attribution and instrument terms
F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac.
F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 1,659,099 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 1,359,545 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein.
F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El Hibri Family Trust except to the extent of his pecuniary interest therein.
F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decendents Trust except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 03, 2021 Filed Dec 8, 2021 02:09 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | OtherCommon Stock | 7,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-21-000634 · elhibri.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,373 F1 · kind: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F4 · ownership.nature: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decedents Trust except to the extent of his pecuniary interest therein. Read SEC document |
| December 03, 2021 Filed Dec 8, 2021 02:09 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | OtherCommon Stock | 9,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-21-000634 · elhibri.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,819 F1 · kind: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F3 · ownership.nature: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Family Trust except to the extent of his pecuniary interest therein. Read SEC document |
| December 03, 2021 Filed Dec 8, 2021 02:09 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | OtherCommon Stock | 107,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-21-000634 · elhibri.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 107,807 F1 · kind: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F2 · ownership.nature: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 59,253 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 48,554 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein. Read SEC document |
| December 03, 2021 Filed Dec 8, 2021 02:10 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 206,434 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-047222 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 206,434 F1 · kind: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F4 · ownership.nature: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decendents Trust except to the extent of his pecuniary interest therein. Read SEC document |
| December 03, 2021 Filed Dec 8, 2021 02:10 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 274,930 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-047222 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 274,930 F1 · kind: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F3 · ownership.nature: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El Hibri Family Trust except to the extent of his pecuniary interest therein. Read SEC document |
| December 03, 2021 Filed Dec 8, 2021 02:10 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 3,018,644 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-047222 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,018,644 F1 · kind: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F2 · ownership.nature: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 1,659,099 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 1,359,545 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 23:33 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 893 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-21-000355 · elhibri.xml · derivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893 Underlying: Common Stock · 893 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs vest in three approximately equal annual installments beginning on June 1, 2022. F3 · derivative.expiration_date: The RSUs vest in three approximately equal annual installments beginning on June 1, 2022. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 23:33 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 2,678 | $0.00 Strike: $26.15 | $0.00 |
DisclosureSEC source: 0001019056-21-000355 · elhibri.xml · derivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,678 Underlying: Common Stock · 2,678 shares Expires 2031-06-01 F1 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on June 1, 2022. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 00:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantRestricted Stock Unit · Derivative | 13,906 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008483 · doc4.xml · derivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,906 Underlying: Common Stock · 13,906 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On February 24, 2021, Mr. El-Hibri was granted 13,906 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. F3 · derivative.expiration_date: On February 24, 2021, Mr. El-Hibri was granted 13,906 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 00:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 27,808 | $0.00 Strike: $93.49 | $0.00 |
DisclosureSEC source: 0000899243-21-008483 · doc4.xml · derivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,808 Underlying: Common Stock · 27,808 shares Expires 2031-02-23 F2 · derivative.exercise_date: On February 24, 2021, Mr. El-Hibri was granted 27,808 stock options vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 23:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Options (Right to Buy) · Derivative | 19,391 | $0.00 Strike: $26.45 | $0.00 |
DisclosureSEC source: 0000899243-20-030866 · doc4.xml · derivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,391 shares Expires 2022-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F6 · derivative.exercise_date: The options vested in three equal installments on March 9 2016, March 9, 2017 and March 9, 2018. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 23:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 19,391 | $88.21 | $1,710,480.11 |
DisclosureSEC source: 0000899243-20-030866 · doc4.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,123,988 F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.69 to $90.00. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 23:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 19,391 | $26.45 | $512,891.95 |
DisclosureSEC source: 0000899243-20-030866 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,143,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 23:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $26.45 | $0.00 |
DisclosureSEC source: 0000899243-20-030866 · doc4.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,391 Underlying: Common Stock · 20,000 shares Expires 2022-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F6 · derivative.exercise_date: The options vested in three equal installments on March 9 2016, March 9, 2017 and March 9, 2018. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 23:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $95.26 | $1,905,200.00 |
DisclosureSEC source: 0000899243-20-030866 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,123,988 F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.85 to $98.49. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 23:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,000 | $26.45 | $529,000.00 |
DisclosureSEC source: 0000899243-20-030866 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,143,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 01:53 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $26.45 | $0.00 |
DisclosureSEC source: 0000899243-20-030431 · doc4.xml · derivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,391 Underlying: Common Stock · 20,000 shares Expires 2022-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F6 · derivative.exercise_date: The options vested in three equal installments on March 9, 2016, March 9, 2017 and March 9, 2018. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 01:53 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $90.74 | $1,814,800.00 |
DisclosureSEC source: 0000899243-20-030431 · doc4.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,123,988 F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.97 to $92.24. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 01:53 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,000 | $26.45 | $529,000.00 |
DisclosureSEC source: 0000899243-20-030431 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,143,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 01:53 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $26.45 | $0.00 |
DisclosureSEC source: 0000899243-20-030431 · doc4.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,391 Underlying: Common Stock · 20,000 shares Expires 2022-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F6 · derivative.exercise_date: The options vested in three equal installments on March 9, 2016, March 9, 2017 and March 9, 2018. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 01:53 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $90.44 | $1,808,800.00 |
DisclosureSEC source: 0000899243-20-030431 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,123,988 F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.40 to $91.62. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 01:53 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,000 | $26.45 | $529,000.00 |
DisclosureSEC source: 0000899243-20-030431 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,143,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document |
| September 24, 2020 Filed Sep 25, 2020 23:00 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 12,535 | $98.85 | $1,239,084.75 |
DisclosureSEC source: 0000899243-20-026348 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,123,988 F1 · kind: The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.84 to $100.44. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 23:00 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 13,000 | $100.58 | $1,307,540.00 |
DisclosureSEC source: 0000899243-20-026348 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,136,523 F1 · kind: The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.86 to $102.63. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 22:25 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $100.68 | $2,013,600.00 |
DisclosureSEC source: 0000899243-20-025750 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,149,523 F1 · kind: The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.07 to $102.18. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 22:25 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $102.48 | $2,049,600.00 |
DisclosureSEC source: 0000899243-20-025750 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,169,523 F1 · kind: The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.13 to $102.27. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 10, 2020 Filed Sep 12, 2020 01:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $102.66 | $2,053,200.00 |
DisclosureSEC source: 0000899243-20-024940 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,189,523 F1 · kind: The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.72 to $104.06. Read SEC document |
| September 09, 2020 Filed Sep 12, 2020 01:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $102.80 | $2,056,000.00 |
DisclosureSEC source: 0000899243-20-024940 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,209,523 F1 · kind: The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.88 to $105.10. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:18 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 170 | Not disclosed Strike: $8.56 | Not disclosed |
DisclosureSEC source: 0001019056-20-000436 · elhibri.xml · derivative · entry 5 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170 Underlying: Common Stock · 170 shares Expires 2030-07-26 F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F7 · derivative.exercise_date: These options will vest in three approximately equal annual installments beginning on the one year anniversary of the date of grant. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:18 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 1,322 | Not disclosed Strike: $8.56 | Not disclosed |
DisclosureSEC source: 0001019056-20-000436 · elhibri.xml · derivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,322 Underlying: Common Stock · 1,322 shares Expires 2030-07-26 F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F6 · derivative.exercise_date: These options vest in full on the one year anniversary of the date of grant. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:18 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 1,785 | Not disclosed Strike: $76.86 | Not disclosed |
DisclosureSEC source: 0001019056-20-000436 · elhibri.xml · derivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,785 shares Expires 2028-06-01 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F5 · derivative.exercise_date: These options provide for vesting in three approximately equal annual installments beginning on May 31, 2019. Prior to July 27, 2020, all but 595 shares of the issuer's common stock underlying this stock option had vested. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:18 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 892 | Not disclosed Strike: $30.10 | Not disclosed |
DisclosureSEC source: 0001019056-20-000436 · elhibri.xml · derivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 892 shares Expires 2027-06-01 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F4 · derivative.exercise_date: These options vested in three approximately equal annual installments beginning on June 1, 2018. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:18 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 1,339 | Not disclosed Strike: $41.16 | Not disclosed |
DisclosureSEC source: 0001019056-20-000436 · elhibri.xml · derivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,339 shares Expires 2026-08-03 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F2 · derivative.exercise_date: These options vested in three approximately equal annual installments beginning on August 3, 2017. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 02, 2020 Filed Feb 18, 2021 02:00 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 3,571 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001019056-21-000140 · elhibri.xml · derivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,571 Underlying: Common Stock · 3,571 shares Expires 2030-07-02 F1 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on July 2, 2021. Read SEC document |
| April 30, 2020 Filed May 2, 2020 00:13 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $74.01 | $1,480,200.00 |
DisclosureSEC source: 0000899243-20-011765 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,229,523 F1 · kind: The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.20 to $74.92. Read SEC document |
| April 29, 2020 Filed May 2, 2020 00:13 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $74.24 | $1,484,800.00 |
DisclosureSEC source: 0000899243-20-011765 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,249,523 F1 · kind: The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.39 to $77.59. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $68.49 | $1,369,800.00 |
DisclosureSEC source: 0000899243-20-011283 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,269,523 F1 · kind: The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.73 to $70.30. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $66.81 | $1,336,200.00 |
DisclosureSEC source: 0000899243-20-011283 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,289,523 F1 · kind: The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.25 to $68.19. Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 22:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $62.47 | $1,249,400.00 |
DisclosureSEC source: 0000899243-20-011020 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,309,523 F1 · kind: The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $63.83. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 01:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 12,537 | $62.58 | $784,565.46 |
DisclosureSEC source: 0000899243-20-010812 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,329,523 F4 · kind: The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c). F5 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.62 to $63.29. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 01:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 6,261 | $62.99 | $394,380.39 |
DisclosureSEC source: 0000899243-20-010812 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,342,060 F1 · kind: These transactions were made by the Reporting Person pursuant to a trading plan adopted by the Reporting Person on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 ("Rule 10b5-1(c)"). F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.53 to $63.66. Read SEC document |
| April 13, 2020 Filed Apr 16, 2020 01:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 17,071 | $62.25 | $1,062,669.75 |
DisclosureSEC source: 0000899243-20-010812 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,348,321 F1 · kind: These transactions were made by the Reporting Person pursuant to a trading plan adopted by the Reporting Person on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 ("Rule 10b5-1(c)"). F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.62 to $63.00. Read SEC document |
| April 09, 2020 Filed Apr 10, 2020 23:13 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 23,716 | $61.83 | $1,466,360.28 |
DisclosureSEC source: 0000899243-20-010651 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,365,392 F3 · kind: These transactions were made by the Reporting Person pursuant to a trading plan adopted by the Reporting Person on February 25, 2020 that is intended to comply with Rule 10b5-1(c). F5 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.71 to $63.98. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 23:13 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 24,362 | $61.34 | $1,494,365.08 |
DisclosureSEC source: 0000899243-20-010651 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,389,108 F3 · kind: These transactions were made by the Reporting Person pursuant to a trading plan adopted by the Reporting Person on February 25, 2020 that is intended to comply with Rule 10b5-1(c). F4 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $62.94. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 23:13 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 13,000 | $60.75 | $789,750.00 |
DisclosureSEC source: 0000899243-20-010651 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,413,470 F1 · kind: The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 ("Rule 10b5-1(c)"). F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $62.10. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 01:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 14,336 | $60.76 | $871,055.36 |
DisclosureSEC source: 0000899243-20-010540 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,426,470 F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $63.48. Read SEC document |
| April 06, 2020 Filed Apr 9, 2020 01:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 28,240 | $60.50 | $1,708,520.00 |
DisclosureSEC source: 0000899243-20-010540 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,440,806 F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $61.38. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 01:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionRestricted Stock Unit · Derivative | 9,794 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006361 · doc4.xml · derivative · entry 11 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,980 Underlying: Common Stock · 9,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F9 · derivative.exercise_date: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. F9 · derivative.expiration_date: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 01:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 9,837 | $56.97 | $560,413.89 |
DisclosureSEC source: 0000899243-20-006361 · doc4.xml · nonDerivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,469,046 F3 · kind: All sales listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F5 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.25 to $58.08. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 01:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 3,854 | $58.42 | $225,150.68 |
DisclosureSEC source: 0000899243-20-006361 · doc4.xml · nonDerivative · entry 6 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,478,883 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.